» Articles » PMID: 9400389

Cardioprotective Effect of Diazoxide and Its Interaction with Mitochondrial ATP-sensitive K+ Channels. Possible Mechanism of Cardioprotection

Overview
Journal Circ Res
Date 1997 Dec 24
PMID 9400389
Citations 233
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies showed a poor correlation between sarcolemmal K+ currents and cardioprotection for ATP-sensitive K+ channel (KATP) openers. Diazoxide is a weak cardiac sarcolemmal KATP opener, but it is a potent opener of mitochondrial KATP, making it a useful tool for determining the importance of this mitochondrial site. In reconstituted bovine heart KATP, diazoxide opened mitochondrial KATP with a K1/2 of 0.8 mumol/L while being 1000-fold less potent at opening sarcolemmal KATP. To compare cardioprotective potency, diazoxide or cromakalim was given to isolated rat hearts subjected to 25 minutes of global ischemia and 30 minutes of reperfusion. Diazoxide and cromakalim increased the time to onset of contracture with a similar potency (EC25, 11.0 and 8.8 mumol/L, respectively) and improved postischemic functional recovery in a glibenclamide (glyburide)-reversible manner. In addition, sodium 5-hydroxydecanoic acid completely abolished the protective effect of diazoxide. While-myocyte studies showed that diazoxide was significantly less potent than cromakalim in increasing sarcolemmal K+ currents. Diazoxide shortened ischemic action potential duration significantly less than cromakalim at equicardioprotective concentrations. We also determined the effects of cromakalim and diazoxide on reconstituted rat mitochondrial cardiac KATP activity. Cromakalim and diazoxide were both potent activators of K+ flux in this preparation (K1/2 values, 1.1 +/- 0.1 and 0.49 +/- 0.05 mumol/L, respectively). Both glibenclamide and sodium 5-hydroxydecanoic acid inhibited K+ flux through the diazoxide-opened mitochondrial KATP. The profile of activity of diazoxide (and perhaps KATP openers in general) suggests that they protect ischemic hearts in a manner that is consistent with an interaction with mitochondrial KATP.

Citing Articles

Adenosine A and A Receptors: Distinct Cardioprotection.

Liang B, Stewart D, Jacobson K Drug Dev Res. 2025; 52(1-2):366-378.

PMID: 39741902 PMC: 11687615. DOI: 10.1002/ddr.1136.


Epigenetics of Homocystinuria, Hydrogen Sulfide, and Circadian Clock Ablation in Cardiovascular-Renal Disease.

Tyagi S Curr Issues Mol Biol. 2024; 46(12):13783-13797.

PMID: 39727952 PMC: 11726923. DOI: 10.3390/cimb46120824.


Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review.

Susilo H, Aldian F, Kencono Wungu C, Alsagaff M, Sutanto H, Multazam C Eur Cardiol. 2024; 19:e21.

PMID: 39588250 PMC: 11588109. DOI: 10.15420/ecr.2024.16.


Cardiac overexpression of a mitochondrial SUR2A splice variant impairs cardiac function and worsens myocardial ischemia reperfusion injury in female mice.

Wexler A, Dooge H, El-Meanawy S, Santos E, Hacker T, Tewari A J Mol Cell Cardiol Plus. 2024; 9.

PMID: 39507427 PMC: 11539194. DOI: 10.1016/j.jmccpl.2024.100088.


Mitochondrial Dysfunction and Ion Imbalance in a Rat Model of Hemodialysis-Induced Myocardial Stunning.

Nie Y, Lin L, Yang Q, Hu J, Sun M, Xiang F Biomedicines. 2024; 12(10).

PMID: 39457714 PMC: 11504215. DOI: 10.3390/biomedicines12102402.